Uterine Fibroids Market Report and Forecast 2025-2034
Description
The uterine fibroids market was valued at USD 13.41 Billion in 2024, driven by advancements in treatment options across the 8 major markets. The market is expected to grow at a CAGR of 7.30% during the forecast period of 2025-2034, with the values likely to reach USD 27.13 Billion by 2034.
Uterine Fibroids Market Overview
Uterine fibroids, which are non-cancerous growths located in the uterus, are frequently seen in women of African descent. Possible symptoms are menstrual bleeding, pelvic pain, frequent urination, bloating, and reproductive problems. Diagnosis is conducted through pelvic exams, imaging procedures, and blood tests, and treatment is tailored according to the symptoms. Increased demand for fertility-preserving treatments and the development of symptomatic treatments are expected to drive the market growth in the forecast period.
Uterine Fibroids Market Growth Drivers
Technological Advancement and Innovation in Treatment Options to Drive Market Growth
Advancements in technology and innovation in treatment options are causing a rise in demand in the market for uterine fibroids. UConn Health, a hospital in the United States, has implemented the Sonata® treatment, demonstrating a revolutionary option to standard surgeries and providing patients with a less invasive choice that allows for quicker recovery and better results. Thus, the advancement in medical technology is one of the primary drivers of the market.
Uterine Fibroids Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Development of Symptomatic Treatments
The current market trend is towards developing symptomatic treatments, with hysterectomy being the main option, but there is a growing focus on non-invasive alternatives that preserve the uterus and fertility, such as uterine-sparing procedures and medical therapies.
Health Literacy to Affect the Market Landscape Significantly
Health literacy is a significant trend in the uterine fibroid treatment landscape in the United States. It impacts decisions on treatment and highlights the importance of healthcare professionals prioritizing patient education to enhance comprehension of conditions and treatment alternatives.
Increased Demand for Fertility-Preserving Treatments
The increasing need for fertility-preserving treatments is set to fuel market expansion. Medical therapies are being emphasized as the primary approach for managing uterine fibroids, aiming to avoid surgery while preserving fertility for women of reproductive age.
Growing Demand for Non-Surgical and Minimally Invasive Treatments
The market is witnessing a trend toward the growing demand for non-surgical options to treat fibroids driven by varying symptom severity. Patients can manage milder symptoms with medication or lifestyle changes, aligning with rising interest in non-invasive treatments.
Uterine Fibroids Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class:
Market Segmentation Based on the Type to Witness Growth
The uterine fibroid market segmentation, based on type, includes subserosal fibroids, intramural fibroids, submucosal fibroids, and pedunculated fibroids, among others. Submucosal fibroids are expected to dominate the market, with emerging economies experiencing category expansion due to their development in the muscle layer of the uterus. Intramural fibroids are also increasing, impacting fertility rates, and requiring treatment.
Uterine Fibroids Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. The United States is expected to dominate the market share owing to the rising prevalence of uterine fibroids, increasing pregnancy complications due to fibroids, and the approval of novel treatment options.
Leading Players in the Uterine Fibroids Market
The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding, and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer Inc. is a United States-based pharmaceutical company specializing in biopharmaceuticals for cardiovascular, metabolic, and women's health. In January 2024, Pfizer Canada collaborated with Sumitomo Pharma Canada to offer MYFEMBREE® for endometriosis and uterine fibroids in Canada.
AbbVie Inc.
AbbVie Inc. based in North Chicago, Illinois, is a pharmaceutical company specializing in the development and commercialization of drugs for chronic and complex diseases. Their focus includes treatments for metabolic, rheumatological, neurological, and skin diseases, as well as hormonal and women's health conditions like hypothyroidism and uterine fibroids.
ObsEva
ObsEva SA is a clinical-stage biopharmaceutical company focusing on developing novel therapies for women's reproductive health and pregnancy. In February 2022, they entered a licensing agreement with Theramex to commercialize Linzagolix, an oral GnRH antagonist for treating uterine fibroids and potentially endometriosis-associated pain.
Bayer AG
Bayer AG is a German pharmaceutical and biotechnology company that focuses on innovative solutions for disease prevention and treatment. They are a key player in the uterine fibroid market, with research efforts on drugs like Vilaprisan for treating symptomatic uterine fibroids.
Other players in the market include AstraZeneca.
Key Questions Answered in the Uterine Fibroids Market Report
Uterine Fibroids Market Overview
Uterine fibroids, which are non-cancerous growths located in the uterus, are frequently seen in women of African descent. Possible symptoms are menstrual bleeding, pelvic pain, frequent urination, bloating, and reproductive problems. Diagnosis is conducted through pelvic exams, imaging procedures, and blood tests, and treatment is tailored according to the symptoms. Increased demand for fertility-preserving treatments and the development of symptomatic treatments are expected to drive the market growth in the forecast period.
Uterine Fibroids Market Growth Drivers
Technological Advancement and Innovation in Treatment Options to Drive Market Growth
Advancements in technology and innovation in treatment options are causing a rise in demand in the market for uterine fibroids. UConn Health, a hospital in the United States, has implemented the Sonata® treatment, demonstrating a revolutionary option to standard surgeries and providing patients with a less invasive choice that allows for quicker recovery and better results. Thus, the advancement in medical technology is one of the primary drivers of the market.
Uterine Fibroids Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Development of Symptomatic Treatments
The current market trend is towards developing symptomatic treatments, with hysterectomy being the main option, but there is a growing focus on non-invasive alternatives that preserve the uterus and fertility, such as uterine-sparing procedures and medical therapies.
Health Literacy to Affect the Market Landscape Significantly
Health literacy is a significant trend in the uterine fibroid treatment landscape in the United States. It impacts decisions on treatment and highlights the importance of healthcare professionals prioritizing patient education to enhance comprehension of conditions and treatment alternatives.
Increased Demand for Fertility-Preserving Treatments
The increasing need for fertility-preserving treatments is set to fuel market expansion. Medical therapies are being emphasized as the primary approach for managing uterine fibroids, aiming to avoid surgery while preserving fertility for women of reproductive age.
Growing Demand for Non-Surgical and Minimally Invasive Treatments
The market is witnessing a trend toward the growing demand for non-surgical options to treat fibroids driven by varying symptom severity. Patients can manage milder symptoms with medication or lifestyle changes, aligning with rising interest in non-invasive treatments.
Uterine Fibroids Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class:
- Progestin-Releasing Intrauterine Device (IUD)& Contraceptives
- Gonadotropin-Releasing Hormone (GnRH) Antagonists
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Non-Hormonal Medications
- Others
- Subserosal Fibroids
- Intramural Fibroids
- Submucosal Fibroids
- Pedunculated Fibroids
- Others
- Hospitals
- Clinics
- Diagnostic Centers
- Research Laboratories
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on the Type to Witness Growth
The uterine fibroid market segmentation, based on type, includes subserosal fibroids, intramural fibroids, submucosal fibroids, and pedunculated fibroids, among others. Submucosal fibroids are expected to dominate the market, with emerging economies experiencing category expansion due to their development in the muscle layer of the uterus. Intramural fibroids are also increasing, impacting fertility rates, and requiring treatment.
Uterine Fibroids Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. The United States is expected to dominate the market share owing to the rising prevalence of uterine fibroids, increasing pregnancy complications due to fibroids, and the approval of novel treatment options.
Leading Players in the Uterine Fibroids Market
The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding, and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer Inc. is a United States-based pharmaceutical company specializing in biopharmaceuticals for cardiovascular, metabolic, and women's health. In January 2024, Pfizer Canada collaborated with Sumitomo Pharma Canada to offer MYFEMBREE® for endometriosis and uterine fibroids in Canada.
AbbVie Inc.
AbbVie Inc. based in North Chicago, Illinois, is a pharmaceutical company specializing in the development and commercialization of drugs for chronic and complex diseases. Their focus includes treatments for metabolic, rheumatological, neurological, and skin diseases, as well as hormonal and women's health conditions like hypothyroidism and uterine fibroids.
ObsEva
ObsEva SA is a clinical-stage biopharmaceutical company focusing on developing novel therapies for women's reproductive health and pregnancy. In February 2022, they entered a licensing agreement with Theramex to commercialize Linzagolix, an oral GnRH antagonist for treating uterine fibroids and potentially endometriosis-associated pain.
Bayer AG
Bayer AG is a German pharmaceutical and biotechnology company that focuses on innovative solutions for disease prevention and treatment. They are a key player in the uterine fibroid market, with research efforts on drugs like Vilaprisan for treating symptomatic uterine fibroids.
Other players in the market include AstraZeneca.
Key Questions Answered in the Uterine Fibroids Market Report
- What was the uterine fibroids market value in 2024?
- What is the uterine fibroids market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on type?
- What is the market segmentation based on the drug class?
- What is the market breakup based on the end user?
- What are the major factors aiding the uterine fibroids market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the uterine fibroids market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Uterine Fibroids Market Overview – 8 Major Markets
- 3.1 Uterine Fibroids Market Historical Value 2018-2024
- 3.2 Uterine Fibroids Market Forecast Value 2025-2034
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Uterine Fibroids Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Uterine Fibroids Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview 2018-2034
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 EU4
- 7.2.4 India
- 7.2.5 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 EU4
- 7.3.4 India
- 7.3.5 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 EU4
- 7.4.4 India
- 7.4.5 Japan
- 8 Uterine Fibroids Market Landscape – 8 Major Markets
- 8.1 Uterine Fibroids Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Uterine Fibroids Market: Product Landscape
- 8.2.1 Analysis by Drug Class
- 8.2.2 Analysis by Type
- 9 Uterine Fibroids Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Uterine Fibroids Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Uterine Fibroids Market Segmentation 218-2034 - 8 Major Markets
- 12.1 Uterine Fibroids Market 2018-2034 by Drug Class
- 12.1.1 Market Overview
- 12.1.2 Progestin-Releasing Intrauterine Device (IUD)& Contraceptives
- 12.1.3 Gonadotropin-Releasing Hormone (GnRH) Antagonists
- 12.1.4 Gonadotropin-Releasing Hormone (GnRH) Agonists
- 12.1.5 Non-Hormonal Medications
- 12.1.6 Others
- 12.2 Uterine Fibroids Market 2018-2034 by Type
- 12.2.1 Market Overview
- 12.2.2 Subserosal Fibroids
- 12.2.3 Intramural Fibroids
- 12.2.4 Submucosal Fibroids
- 12.2.5 Pedunculated Fibroids
- 12.2.6 Others
- 12.3 Uterine Fibroids Market 2018-2034 by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Clinics
- 12.3.4 Diagnostic Centers
- 12.3.5 Research Laboratories
- 12.3.6 Others
- 12.4 Uterine Fibroids Market 2018-2034 by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Uterine Fibroids Market 218-2034
- 13.1 United States Uterine Fibroids Market 2018-2034 by Drug Class
- 13.1.1 Market Overview
- 13.1.2 Progestin-Releasing Intrauterine Device (IUD)& Contraceptives
- 13.1.3 Gonadotropin-Releasing Hormone (GnRH) Antagonists
- 13.1.4 Gonadotropin-Releasing Hormone (GnRH) Agonists
- 13.1.5 Non-Hormonal Medications
- 13.1.6 Others
- 13.2 United States Uterine Fibroids Market 2018-2034 by Type
- 13.2.1 Market Overview
- 13.2.2 Subserosal Fibroids
- 13.2.3 Intramural Fibroids
- 13.2.4 Submucosal Fibroids
- 13.2.5 Pedunculated Fibroids
- 13.2.6 Others
- 13.3 United States Uterine Fibroids Market 2018-2034 by End User
- 13.3.1 Market Overview
- 13.3.2 Hospitals
- 13.3.3 Clinics
- 13.3.4 Diagnostic Centers
- 13.3.5 Research Laboratories
- 13.3.6 Others
- 14 EU-4 and United Kingdom Uterine Fibroids Market 218-2034
- 14.1 EU-4 and United Kingdom Uterine Fibroids Market 2018-2034 by Drug Class
- 14.1.1 Market Overview
- 14.1.2 Progestin-Releasing Intrauterine Device (IUD)& Contraceptives
- 14.1.3 Gonadotropin-Releasing Hormone (GnRH) Antagonists
- 14.1.4 Gonadotropin-Releasing Hormone (GnRH) Agonists
- 14.1.5 Non-Hormonal Medications
- 14.1.6 Others
- 14.2 EU-4 and United Kingdom Uterine Fibroids Market 2018-2034 by Type
- 14.2.1 Market Overview
- 14.2.2 Subserosal Fibroids
- 14.2.3 Intramural Fibroids
- 14.2.4 Submucosal Fibroids
- 14.2.5 Pedunculated Fibroids
- 14.2.6 Others
- 14.3 EU-4 and United Kingdom Uterine Fibroids Market 2018-2034 by End User
- 14.3.1 Market Overview
- 14.3.2 Hospitals
- 14.3.3 Clinics
- 14.3.4 Diagnostic Centers
- 14.3.5 Research Laboratories
- 14.3.6 Others
- 15 Japan Uterine Fibroids Market 218-2034
- 15.1 Japan Uterine Fibroids Market 2018-2034 by Drug Class
- 15.1.1 Market Overview
- 15.1.2 Progestin-Releasing Intrauterine Device (IUD)& Contraceptives
- 15.1.3 Gonadotropin-Releasing Hormone (GnRH) Antagonists
- 15.1.4 Gonadotropin-Releasing Hormone (GnRH) Agonists
- 15.1.5 Non-Hormonal Medications
- 15.1.6 Others
- 15.2 Japan Uterine Fibroids Market 2018-2034 by Type
- 15.2.1 Market Overview
- 15.2.2 Subserosal Fibroids
- 15.2.3 Intramural Fibroids
- 15.2.4 Submucosal Fibroids
- 15.2.5 Pedunculated Fibroids
- 15.2.6 Others
- 15.3 Japan Uterine Fibroids Market 2018-2034 by End User
- 15.3.1 Market Overview
- 15.3.2 Hospitals
- 15.3.3 Clinics
- 15.3.4 Diagnostic Centers
- 15.3.5 Research Laboratories
- 15.3.6 Others
- 16 India Uterine Fibroids Market 218-2034
- 16.1 India Uterine Fibroids Market 2018-2034 by Drug Class
- 16.1.1 Market Overview
- 16.1.2 Progestin-Releasing Intrauterine Device (IUD)& Contraceptives
- 16.1.3 Gonadotropin-Releasing Hormone (GnRH) Antagonists
- 16.1.4 Gonadotropin-Releasing Hormone (GnRH) Agonists
- 16.1.5 Non-Hormonal Medications
- 16.1.6 Others
- 16.2 India Uterine Fibroids Market 2018-2034 by Type
- 16.2.1 Market Overview
- 16.2.2 Subserosal Fibroids
- 16.2.3 Intramural Fibroids
- 16.2.4 Submucosal Fibroids
- 16.2.5 Pedunculated Fibroids
- 16.2.6 Others
- 16.3 India Uterine Fibroids Market 2018-2034 by End User
- 16.3.1 Market Overview
- 16.3.2 Hospitals
- 16.3.3 Clinics
- 16.3.4 Diagnostic Centers
- 16.3.5 Research Laboratories
- 16.3.6 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Bayer AG
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Developments
- 23.2.5 Certifications
- 23.3 AstraZeneca
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Developments
- 23.3.5 Certifications
- 23.4 Pfizer, Inc.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Developments
- 23.4.5 Certifications
- 23.5 AbbVie Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Developments
- 23.5.5 Certifications
- 23.6 ObsEva
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Developments
- 23.6.5 Certifications
- 24 Uterine Fibroids Market - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
